Exploring Interactions Between Growth Hormone and the Microbiome

NCT ID: NCT03327207

Last Updated: 2020-07-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-01

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to characterize the microbiome and metabolomics of children with Growth Hormone (GH) deficiency, prior GH treatment initiation and compare it to healthy children

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Hormone Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Children who receive Growth hormone treatment. Non Interventional

Non Interventional

Intervention Type OTHER

Non Interventional

Control group

Healthy children . Non Interventional

Non Interventional

Intervention Type OTHER

Non Interventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non Interventional

Non Interventional

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children with GH deficiency

Exclusion Criteria

* Turner syndrome
* End state renal disease (ESRD)
* Prader-Willi syndrome
* Systemic illness
* Antibiotics/Antifungal in the last 3m
Minimum Eligible Age

3 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Weizmann Institute of Science

OTHER

Sponsor Role collaborator

Rambam Health Care Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pediatric endocrinology unit rambam medical center

Haifa, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Smadar Shilo, Dr

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Smadar Shilo, MD

Role: primary

97247774400

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0132-17 RMB CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Short Stature Related Distress
NCT01246219 COMPLETED PHASE4
GH and Cardiovascular Risk Factors
NCT01877512 COMPLETED PHASE4